Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03679767 · ClinicalTrials.gov registry record · Phase 2
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
A Phase 2 study of Metastatic Melanoma and Metastatic Non Small Cell Lung Cancer, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
- 20
- Study locations
NCT03679767: Completed Phase 2 study of Metastatic Melanoma and Metastatic Non Small Cell Lung Cancer, sponsored by Incyte Corporation.
NCT03679767 is a Phase 2 study of Metastatic Melanoma and Metastatic Non Small Cell Lung Cancer that has completed, run by Incyte Corporation. The registered enrollment target is 121 participants, above the 82-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (48% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03679767, a Phase 2 study of Metastatic Melanoma and Metastatic Non Small Cell Lung Cancer, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.
Primary Outcome
ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1), as determined by the investigator, at any post-Baseline visit until new anti-cancer therapy or first Progressive Disease. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a redu
Conditions Studied
Interventions
- DRUG Retifanlimab
Study Locations (20)
Texas
- Texas Oncology Surgical Specialists - Austin Central - Austin
- Coastal Bend Cancer Center - Corpus Christi
- AIM Trials, LLC - Plano
- Texas Oncology - San Antonio Northeast - San Antonio
- Oncology and Hematology Associates of Southwest Virginia, Inc. - The Woodlands
- Texas Oncology - Waco - Waco
California
- California Cancer Associates for Research and Excellence, Inc. - Fresno
- California Cancer Associates for Research and Excellence - Fresno
- California Cancer Associates for Research and Excellence, Inc. - San Marcos
- St Joseph Heritage Healthcare - Santa Rosa
- St. Joseph Health Medical Group - Annadel Medical Group - Santa Rosa
Other
- LKH Graz - Graz
- Medizinische Universitat Innsbruck - Innsbruck
Colorado
- Rocky Mountain Cancer Centers - Denver - Midtown - Denver
Delaware
- Christiana Care Helen F. Graham Cancer Center - Newark
Maryland
- Rcca Md, Llc - Bethesda
New Jersey
- VA New Jersey Health Care System - East Orange
New York
- New York Oncology Hematology - Albany - Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2019-01-09 |
| Est. Completion | 2022-06-28 |
| Phase | Phase 2 |
What the finished NCT03679767 record still lists
NCT03679767 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, above the 82-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (48% higher).
The record links to 7 conditions, with Metastatic Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Retifanlimab is the first listed.
NCT03679767 names 20 study sites across 10 states, led by Texas, California, Other.
Frequently Asked Questions
What is clinical trial NCT03679767 about?
NCT03679767 is a clinical study titled "A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)". The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.
What is the current status of trial NCT03679767?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2019-01-09. Estimated completion is 2022-06-28.
What conditions does trial NCT03679767 study?
This clinical trial studies the following conditions: Metastatic Melanoma, Metastatic Non Small Cell Lung Cancer, Unresectable Melanoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Urothelial Cancer.
What interventions are being tested in trial NCT03679767?
The interventions under investigation include: Retifanlimab (DRUG).
Who is sponsoring clinical trial NCT03679767?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03679767 being conducted?
This trial has 20 study locations across California, Colorado, Delaware, Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03679767's enrollment target sits among peer trials
121 17th of 91 higher than 75 of 91 other Metastatic Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
RECRUITING · Phase 2
-
Cryoablation+Ipilimumab+Nivolumab in Melanoma
RECRUITING · Phase 2
-
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
RECRUITING · Phase 2
-
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
RECRUITING · Phase 2
-
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI